Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that dutasteride, identified through a drug repurposing strategy, showed the potential to reduce neuroinflammation and cognitive impairment in LPS-stimulated models.

This study found that finasteride may reduce inappropriate sexual behaviors in geriatric patients with vascular dementia and benign prostate hyperplasia without serious side effects, though some patients required additional medications.

This review discusses the risk of central nervous side effects, such as dementia and depression, from drugs used to treat lower urinary symptoms related to benign prostatic hyperplasia, and highlights inconsistent evidence across different medications.

This review discusses the sexual side effects of medical and surgical treatments for benign prostatic hyperplasia, such as erectile dysfunction and changes in ejaculation, but presents no new clinical findings.

This study classified dutasteride, fesoterodine, and finasteride as beneficial for older or frail elderly patients, while suggesting caution or avoidance of α-blockers and antimuscarinics in this group.

This study found that long-term dutasteride therapy in men with benign prostatic hyperplasia worsened erectile dysfunction, reduced testosterone levels, and increased blood glucose and lipid profile, indicating negative metabolic impacts.

This study found that patients with bladder outlet obstruction and moderately enlarged prostates are likely to successfully discontinue the a-blocker doxazosin after 9 months of combination therapy with finasteride.

This study found that in male mice, microglial changes due to a Parkinson's-like lesion were influenced by sex hormones, with dutasteride treatment preventing some effects.

This hypothesis paper suggests that sexual and cognitive dysfunctions reported by some men after using finasteride and dutasteride may stem from vascular and tissue changes in penile tissue triggering broader inflammatory effects.

This study hypothesizes that the sulfonamide group in tamsulosin might contribute to its association with intraoperative floppy iris syndrome.

This report discusses Titanflow as a potential improvement in male urinary health by focusing on the detrusor muscle rather than prostate size, suggesting it may offer relief where other supplements have limited effectiveness.

This study found that dutasteride may offer neuroprotective effects on dopaminergic neurons in an animal model of early-stage Parkinson's disease, suggesting potential therapeutic use.

In this study using a rat model, discontinuing dutasteride improved some relaxant responses but did not fully restore erectile function, indicating a potential time-dependent detriment of the drug.

In this study, researchers identified six novel prognostic biomarkers for bladder cancer and developed a predictive model that effectively stratifies patients into high-risk and low-risk groups based on immune cell infiltration differences and gene expression.

This review discusses the classification and treatment of ejaculatory dysfunction, outlining both pharmacotherapy and behavioral therapy as primary interventions, but does not present new clinical findings.

This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.

This abstract outlines a study evaluating dutasteride's effect on perioperative bleeding during transurethral resection of the prostate, but does not report any new clinical results.

This review discusses the role of norepinephrine release and protein kinase C activation in the development of benign prostatic hypertrophy, suggesting potential targets for new therapies, but it reports no new clinical results.

Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.

This study suggests that glaucoma patients may face increased risk of optic nerve injury if prescribed medications that can lower blood pressure.

This study observed that long-term treatment with 5ARIs in men with LUTS/BPH was linked to worsening sexual function, whereas doxazosin alone had minimal negative impact.

This letter to the editor discusses the relationship between lower urinary tract symptoms and erectile dysfunction as reported in a previous study, but presents no new findings.

This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.

This article discusses the management of male lower urinary tract symptoms (LUTS) and presents randomized placebo-controlled study results on finasteride use, but it reports no new clinical findings.

In this interventional study, researchers observed that women with stress urinary incontinence experienced significant symptom improvement one and three months after receiving autologous platelet-rich plasma injections, with no notable impact on sexual function or adverse reactions reported.

This case report discusses an 80-year-old man whose hyponatremia likely resulted from multiple causes, including diuretic use, excessive water intake, and urinary retention, emphasizing cautious management in older adults.

This study found that 44.3% of patients with benign prostatic hyperplasia experienced high anxiety levels, which were significantly associated with residual symptoms and demographic factors.

This study found that long-term administration of tamsulosin hydrochloride 0.2 mg is effective, safe, and well-tolerated for improving symptoms and quality of life in patients with LUTS of BPH.

This study concluded that repeated platelet-rich plasma injections provided greater and more consistent improvements in stress urinary incontinence symptoms compared to pelvic floor muscle training.